Sage Journals: Discover world-class research

Abstract

Background:

In efforts to reduce misuse of opioids, new abuse deterrent formulations of medications have been developed. Insurers increasingly give abuse-deterrent opioid formulations preferred formulary status, which can result in required formulation rotation for patients. Xtampza® (oxycodone myristate extended-release) is an abuse-deterrent opioid formulation that maintains its extended-release properties with any physical manipulation. Blood levels of oxycodone myristate extended-release (OxyM-ER) may vary with dietary caloric and fat intake.

Case Description:

A woman with metastatic breast carcinoma had severe myalgias and arthralgias well-managed with oxycodone hydrochloride extended-release (OxyHCl-ER) and hydrocodone/acetaminophen. A switch from OxyHCl-ER to OxyM-ER resulted in worsened pain management, decreased functional status, and a referral to palliative care (PC). Recognizing calorie-depending pharmacokinetic variability with OxyM-ER, the interdisciplinary PC team obtained a detailed dietary history from the patient, which revealed a low-fat, low-calorie healthy diet with inconsistent meals. After repeated education, the patient changed her diet and had improved pain and functional status without increasing her total daily opioid dose.

Conclusion:

The efficacy of OxyM-ER may be compromised in patients with cancer experiencing anorexia, decreased or inconsistent food intake, or low-fat/low-calorie diets. An interdisciplinary team approach can improve pain control in the setting of “forced” formulary switches to OxyM-ER.

Keywords

opioids opioid formulations palliative care oxycodone oxycodone extended-release oxycodone myristate Xtampza abuse-deterrent bioavailability patient education

Get full access to this article

View all access options for this article.

References

Nokhodchi

Raja

Patel

Asare-Addo

. The role of oral controlled release matrix tablets in drug delivery systems. BioImpacts. 2012;2(4):175–187.

Guidance for Industry Abuse-Deterrent Opioids—Evaluation and Labeling. US Department of Health and Human Services, Food and Drug Administration and Center for Drug Evaluation and Research. FDA Guid Ind. 2015; 1–26. https://www.fda.gov/files/drugs/published/Abuse-Deterrent-Opioids-Evaluation-and-Labeling.pdf

Gudin

Levy-Cooperman

Kopecky

Fleming

. Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med. 2015;16(11):2142–2151.

Xtampza [Full Prescribing Information]. Collegium Pharmaceutical, Inc; 2018.

Nallani

. Food Effect with Xtampza ER. Food and Drug Administration, Center for Drug Evaluation and Research. Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee. 2015.

FDA Advisory Committee Briefing Document: Xtampza ER. FDA Advisory Committee Meeting. 1–93. 2015.

Tisdale

. Cancer anorexia and cachexia. Nutrition. 2001;17(5):438–442.

Muscaritoli

Simone

Alessio

, et al. Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study. Oncotarget. 2017;8(45):79884–79896.